12:02 , Dec 17, 2018 |  BC Extra  |  Company News

Proteomics company Seer launches with $36M

Counting nanoparticle pioneer Omid Farokhzad, Robert Langer and Biogen Inc. (NASDAQ:BIIB) vet Philip Ma among its founders, proteomic data company Seer Inc. (South San Francisco, Calif.) launched Monday to develop liquid biopsy tests for early...
14:33 , Dec 11, 2018 |  BC Extra  |  Politics & Policy

No SCOTUS appeal for CRISPR patent battle

As expected, Regents of University of California did not file a petition for writ of certiorari by Monday's deadline, meaning its legal battle with Broad Institute of MIT and Harvard over ownership of foundational CRISPR-Cas9...
02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
21:59 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
23:59 , Dec 4, 2018 |  BC Extra  |  Preclinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Patient sample, cell culture and mouse studies suggest inhibiting VEGF-A, VEGFR-2 or HIF1 could help treat Clostridium difficile infection (CDI). In serum samples from patients, levels of VEGF-A were higher than in samples...
19:06 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...